Navigation Links
Ennaid Therapeutics Prioritizes Zika Virus Rapid Drug Development in Wake of Crisis

ALPHARETTA, Ga., Feb. 14, 2016 /PRNewswire/ -- Ennaid Therapeutics, located in Alpharetta, GA is developing therapeutic cures to help the millions of people worldwide when infected with the mosquito-borne disease, Zika Virus, now named a global public health emergency by the World Health Organization and the CDC. The global health community is urging caution and care in response to Zika's explosive spread and is calling for rapidly stepped up efforts by researchers to find therapeutics and vaccines for those who contract it.

For years, Ennaid Therapeutics has been committed to developing cures for mosquito-borne diseases, including Dengue, Chikungunya and Zika viruses – and is now advancing its work on Zika to address the urgent global need.

Zika Virus

Zika is linked to microcephalic birth defects and possible eye damage in babies. The virus, which is transmitted by Aedes species mosquito, has infected 1 million Brazilians and 50+ people in the United States. An estimated 4 million infections are expected in the Americas in 2016. Zika's risk to pregnant women is a top priority, according to the CDC.

"Zika virus, which is now our focus, has been in our ten-product pipeline for years, and we will continue developing cures for the growing numbers of Dengue, West Nile and Chikungunya sufferers, among other mosquito-borne diseases," says Darnisha Harrison, Ennaid Therapeutics' CEO.

Please see link below of Discovery Channel's "Innovations with Ed Begley, Jr.", in which Ennaid Therapeutics will be featured:

Ennaid Therapeutics' Science

  • Our peptide fusion inhibitors show significant inhibition against many Flaviviridae family of viruses, such as Dengue and possibly Zika; both carried by the Aedes species mosquito, and both of the flavivirus genus
  • Our peptide's stem mimic the stem of many Flaviviridae viruses, thus inhibiting viral infections
  • Zika stem is a very close match to our peptide's stem and  feasibility studies are underway.
  • Already planned development studies will determine our peptide's inhibition against Zika virus in vivo and safety in pregnancy
  • Our fast-track development strategy will then allow Ennaid Therapeutics to immediately begin clinical trials, as funding is secured
  • Currently there are safe and effective commercialized peptide fusion inhibitors, such as Enfuvirtide, brand name Fuzeon

Ennaid Therapeutics

Founded in 2012, Ennaid Therapeutics is developing a proprietary platform technology of flavivirus fusion inhibitors that show significant inhibition against flavivirus infectivity, such as Dengue, et al. Their rapid development plan has the potential to safely and quickly bring a Zika virus therapeutic cure to market in record time.

Darnisha Harrison, Ennaid Therapeutics CEO

Formerly a Microbiologist and Chemist, Ms. Harrison is a nationally recognized pharmaceutical entrepreneur by Newsweek magazine. With 22 years' experience in the life sciences, she is a member of the American Association for the Advancement of Science and the New York Academy of Sciences. She received a Bachelor of Science in Microbiology and a Minor in Chemistry from LSU.

For interviews, investment or more information contact:
Gigi Gilbert, Public Relations, Phone: +404-309-7034, Email:

SOURCE Ennaid Therapeutics
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. Novelos Therapeutics Provides Product Pipeline Update
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
4. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
8. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
9. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
10. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
(Date:6/19/2019)... , ... June 19, 2019 , ... ... exclusively for the promotion of social welfare and protection of physicians’ rights, asserts ... than the previous revision and still rely on narrow guidelines as a basis ...
(Date:6/19/2019)... ... June 19, 2019 , ... Center for Vein Restoration (CVR) CEO and Founder, ... CEOs in 2019 . Glassdoor , one of the world’s largest job ... leaders that employees love working for throughout North America and parts of Europe. Dr. ...
(Date:6/19/2019)... Pa. (PRWEB) , ... June 19, 2019 , ... ... nuclear receptor and in vitro toxicology testing solutions, announced the addition of the ... kit expands INDIGO’s existing in vitro toxicology offerings and allows researchers to perform ...
Breaking Medicine Technology:
(Date:6/25/2019)... DETROIT (PRWEB) , ... June 25, 2019 , ... Women’s ... and raised in Louisiana and has been a practicing midwife for over 3 years. ... years. April received her Master’s in Nursing from Frontier University and her undergraduate from ...
(Date:6/25/2019)... ... June 25, 2019 , ... Smile Brands Inc., one of ... than 400 affiliated offices across 17 states, is pleased to announce its latest ... will provide full-service administrative support to the practice, which includes purchasing, payroll, accounting, ...
(Date:6/25/2019)... ... June 25, 2019 , ... The Global Smile Foundation will ... July thanks to 15-year-old Kylie Azizzadeh’s efforts fundraising for the mission. She has already ... before the mission takes place on July 15, 2019. , In 2018, Kylie ...
(Date:6/24/2019)... ... 2019 , ... innovaTel Telepsychiatry, a leading provider of psychiatric ... Advisory Board (SAB) to help inform the Company’s efforts to bring telepsychiatry services ... , We are honored to announce that Linda Rosenberg, immediate past President and ...
(Date:6/24/2019)... (PRWEB) , ... June 24, 2019 , ... Exercising on ... cardio, people often try to mitigate this by running on softer surfaces, such as ... made of a rubber composite. Why not be able to have shock-absorption benefits ...
Breaking Medicine News(10 mins):